First Manhattan’s CASI Pharmaceuticals CASI Stock Holding History

First Manhattan’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,000	Closed	-$61K	–	1380
2020 Q1	$61K	Hold	3,000	–	–	﹤0.01%	811
2019 Q4	$92K	Hold	3,000	–	–	﹤0.01%	804
2019 Q3	$100K	Hold	3,000	–	–	﹤0.01%	799
2019 Q2	$96K	Hold	3,000	–	–	﹤0.01%	824
2019 Q1	$86K	Hold	3,000	–	–	﹤0.01%	857
2018 Q4	$120K	Hold	3,000	–	–	﹤0.01%	767
2018 Q3	$140K	Hold	3,000	–	–	﹤0.01%	779
2018 Q2	$246K	Buy	+3,000	New	+$202K	﹤0.01%	661

Other funds holding CASI

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

First Manhattan's CASI Position: Q2 2020 in Review

First Manhattan sold out of CASI Pharmaceuticals (CASI) in Q2 2020, closing a stake of 3,000 shares — an estimated $61K sold.

First Manhattan first reported a position in CASI in Q2 2018 and held it in 8 quarters. The position peaked at $246K in Q2 2018. 59 funds tracked by Wall St. Rank hold CASI as of Q2 2020.

First Manhattan reported no remaining CASI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Manhattan sold 3,000 CASI Pharmaceuticals shares in Q2 2020, an estimated $61K.
First Manhattan first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 8 quarters.
First Manhattan's CASI Pharmaceuticals position peaked at $246K in Q2 2018.
59 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.